Polymateria receives £15m boost for roll-out of its Biotransformation technology
Will UK borrowing highs lead to new austerity measures?
NextGen Nano: Next Generation of Nanotechnology
Over a quarter of City’s finance teams not returning to the office this month
According to research performed by accounting and consultancy firm, Theta Financial Reporting, over 26% of Brits surveyed say their company’s finance teams will not be returning to the office with other staff this month, and will now work at home for the majority of the time. It added that 24% of those surveyed said that their employer hadn’t explored any flexible working options to help staff return to work.
It continued, stating that 70% of City-based staff now feel uncomfortable commuting to work via public transport, with these people also saying that journeys to and from the office will become one of the most stressful parts of the day. Also, according to the company’s research, some 29% of business leaders said they had permanently streamlined their team in response to the COVID pandemic, with many finding certain roles to be unnecessary luxuries. The company are in favour of flexible working arrangements, and said that its research illustrated a lack of desire to return to pre-pandemic working conditions. Speaking on the report, Theta Financial Reporting Founder and Managing Director, Chris Biggs, commented:“This research demonstrates the clear desire for people both in the Capital and finance teams not to return to their pre-COVID working environments, regardless of the calls from the Prime Minister to return to normality before Christmas.”
“Many businesses have adapted to working away from the office and with so many people caring for vulnerable relatives, friends and children, it seems people do not want to return in July or August, despite the easing of lockdown restrictions. This will have a significant impact on how our workplaces will look beyond lockdown.”
“From the commute to boosted productivity when working from home, there are numerous benefits to flexible working that this period has uncovered for millions of employers and employees alike. Business leaders would do well to realise this and adapt now to pivot their business, remove unnecessary overheads and plan for a post-COVID future.”
The future of potential work-from-home or home-office hybrid arrangements has already been an issue widely discussed during lockdown, and it will be interesting to see whether some of the suggestions made will come into force or simply fade away as a passing fad. For now, though, it is important that whatever working arrangements are in place encourage both the greatest extent of staff safety, and productivity.
Instem shares rally on successful fundraise and revenue spike
It continued, noting that it raised £15.75 million in its ‘oversubscribed’ fundraise, which was approved by shareholders on the July 16 and completed post-period-end. With the proceeds of the fundraiser, the company said it had identified ‘substantial’ targets, and would focus on adding bolt-on acquisitions.
Instem stated that it had suffered a setback with its inability to undertake client site based professional services and secure new software licences in the academic segment. However, the period also yielded positive news, with recent acquisition Leadscope trading stronger than anticipated.
Instem response
Commenting on the results, CEO Phil Reason, stated: “Trading during the Period highlighted the resilience of our operations and the dedication of the entire Instem team as the Company continued to grow despite the COVID-19 backdrop. We have been delighted to directly contribute to our clients’ COVID-19 vaccine and therapy-related R&D activities and remain committed to prioritising these efforts over the second half. Following completion of the fundraise, we also aim to drive revenues and margins as we look to further consolidate the market.”Investor insights
Following the update, Instem shares rallied by 1.32% or 6.00p, to 460.00p per share 20/07/20 12:34 BST. This is far ahead of its year-to-date nadir of 375.00p on March 25, but below its 530.00p high on June 3. The company’s p/e ratio currently stand at 23.52.Synairgen share price jumps over 380% on positive COVID-19 treatment results
“We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’,” said Richard Marsden, CEO of Synairgen.
The Synairgen CEO also pointed to positive results relating to the recovery of patients to a level of fitness similar to before they caught COVID-19.
“It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2.”
“In addition, SNG001 has significantly reduced breathlessness, one of the main symptoms of severe COVID-19. This assessment of SNG001 in COVID-19 patients could signal a major breakthrough in the treatment of hospitalised COVID-19 patients. Our efforts are now focused on working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible.”
